NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the "Company") a special purpose acquisition company, announced today that on July 2, 2024, its sponsor, Vision Sensing, LLC, deposited $51,016.10 into the Company's trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from July 3, 2024, to August 3, 2024 (the "Extension"). This is the third of up to six one-m ...

The Extension provides the Company with additional time to complete its initial business combination (the "Business Combination") with Mediforum Co. Ltd., a Korean company ("Mediforum"), pursuant to a merger agreement dated January 12, 2024 (as it may be amended and/or restated from time to time, the "Merger Agreement"). About Vision Sensing Acquisition Corp. Forward-Looking Statements In connection with the proposed transaction, VSAC and Mediforum intend to cause a registration statement on Form F-4 or S-4 ...

文章核心观点 - Vision Sensing Acquisition Corp.（VSAC）宣布延长完成初始业务合并的时间，拟与韩国生物技术公司Mediforum进行合并，双方介绍了自身情况及合作相关安排 [13][14] 公司介绍 - Vision Sensing Acquisition Corp.是一家特殊目的收购公司（SPAC），旨在收购一家私营科技公司 [15] - Mediforum Co., Ltd是一家韩国领先的生物技术公司，成立于2015年，总部位于韩国首尔，致力于改善阿尔茨海默病和神经性疼痛患者的生活质量，其旗舰产品PM012处于阿尔茨海默病2b期试验阶段，MF018处于化疗引起的周围神经病变2期试验阶段 [14] 业务合并相关情况 - 公司将初始业务合并日期从2024年7月3日延长至8月3日，其发起人Vision Sensing, LLC拟在7月3日前向公司信托账户存入51,016.10美元，公司将向发起人发行同等金额的无息无担保本票作为资金回报，这是公司根据修订后的公司章程可获得的最多六次为期一个月延期中的第二次 [13] - 公司与Mediforum签订了《合并协议和计划》，Norwich Capital Limited和American General Business Association & SME Overseas IPO Capital Group担任Mediforum的首席顾问和联合顾问，Loeb & Loeb LLP和Next Law LLP分别担任其美国和韩国法律顾问；EF Hutton和ARC Group Limited分别担任VSAC的资本市场顾问和财务顾问 [6][7][8] 信息披露与联系方式 - VSAC、Mediforum及其相关人员可能被视为拟议交易中征集代理投票的参与者，相关信息将在提交给美国证券交易委员会（SEC）的注册声明中的代理声明/招股说明书中披露，股东和潜在投资者应在相关文件发布后仔细阅读再做决策，可从指定来源免费获取这些文件 [4] - Vision Sensing Acquisition Corp.联系人：董事长兼首席执行官George Peter Sobek，邮箱georgesobek@hotmail.co.uk；Mediforum Co., Ltd联系人：董事长兼创始人Chankyu Kim，邮箱kimchankyu@gmediforum.com，首席执行官Jae Eon Jung，邮箱jejung@gmediforum.com [5][19] 前瞻性声明 - 新闻稿包含前瞻性声明，实际结果可能与预期不同，影响因素包括合并协议终止、法律诉讼、无法完成业务合并、监管审批延迟或无法获得、上市失败等 [16]

About Mediforum About Vision Sensing Acquisition Corp. Forward-Looking Statements Additional Information and Where to Find It VSAC, Mediforum, and their respective directors, executive officers, and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from VSAC's stockholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of VSAC's stock ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission File Number: 001-40983 Vision Sensing Acquisition Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40983 Vision Sensing Acquisition Corp. (Exact name of registrant as specified in its charter) | Delaware | 87-2323481 | | --- | --- | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission File Number: 001-40983 Vision Sensing Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 87-2323481 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission File Number: 001-40983 Vision Sensing Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 87-2323481 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission File Number: 001-40983 Vision Sensing Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 87-2323481 (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 | Title of Each Class: | Trading Symbol(s) | Name of Each Exchange on Which Registered: | | --- | --- | --- | | Units, each consisting of one share of Class A | | | | Common Stock and three-quarters of one | | | | Redeemable Warrant | VSACU | The Nasdaq Stock Market LLC | | Class A Common Stock, $0.0001 par value per | | | | share ...